0001179110-17-003751.txt : 20170303 0001179110-17-003751.hdr.sgml : 20170303 20170303091041 ACCESSION NUMBER: 0001179110-17-003751 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170301 FILED AS OF DATE: 20170303 DATE AS OF CHANGE: 20170303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McMahon Gerald PhD CENTRAL INDEX KEY: 0001290747 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 17661622 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 4 1 edgar.xml FORM 4 - X0306 4 2017-03-01 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001290747 McMahon Gerald PhD C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 1 0 0 0 Common Stock, par value $.001 per share 2017-03-01 4 F 0 32927 3.54 D 234429 D On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017. The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. Pursuant to the Severance Agreement, on March 1, 2017, the Issuer issued 59,182 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 32,927 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. /s/ Avery W. Catlin, attorney-in-fact for Gerald McMahon 2017-03-03